Top-line data demonstrate efficacy, safety of teprotumumab for thyroid eye disease

Most adults with thyroid eye disease who experienced meaningful improvement in proptosis after 21 weeks of teprotumumab treatment maintained proptosis response at week 72 without additional treatment, according to top-line data.
Data from the OPTIC 48-week off-treatment follow-up period demonstrated that 56% of participants who received teprotumumab-trbw (Tepezza, Horizon Therapeutics) and were proptosis responders at week 24 in the OPTIC trial maintained their proptosis response at week 72 without receiving additional thyroid eye disease treatment. In a second study, OPTIC-X, 89% of

Full Story →